10-K: Helius Medical Technologies Reports 2023 Financial Results, Outlines Path to Reimbursement

Helius Medical Technologies' 2023 annual report details ongoing losses, a manufacturing transition, and progress towards reimbursement for its PoNS device.

Summary

• Helius Medical Technologies reported a net loss of $8.9 million for 2023, compared to a $14.1 million loss in 2022.
• The company's cash used in operating activities was $10.4 million in 2023, down from $14.3 million in the previous year.
• Revenue from product sales was $0.6 million in 2023, a decrease from $0.8 million in 2022, primarily due to lower sales in Canada.
• The company is transitioning manufacturing of the PoNS device from Key Tronic to Minnetronix, expected to be completed by mid-2024.
• HCPCS codes for the PoNS controller and mouthpiece were received in February 2024, effective April 1, 2024, which is a step towards Medicare reimbursement.
• The company expects it will take at least 24 months to obtain broad coverage and reimbursement among government and private payers once the HCPCS codes become effective.
• The company had $5.2 million in cash as of December 31, 2023, and expects to need additional financing beyond the second quarter of 2024.
• The company's independent auditor has raised substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive developments, such as the receipt of HCPCS codes and a decrease in operating losses, the company's ongoing losses, need for additional financing, and the auditor's going concern warning create a negative outlook.

Positives

• The company's net loss decreased in 2023 compared to 2022.
• Cash used in operating activities decreased in 2023 compared to 2022.
• The company received HCPCS codes for the PoNS device, a key step towards reimbursement.
• The company is actively working to secure reimbursement from commercial insurers and Medicare.
• The company is transitioning to a new manufacturer, which may improve production efficiency.

Negatives

• The company continues to experience significant losses.
• Revenue from product sales decreased in 2023 compared to 2022.
• The company's independent auditor has raised substantial doubt about its ability to continue as a going concern.
• The company expects to need additional financing beyond the second quarter of 2024.
• The company anticipates it will take at least 24 months to obtain broad coverage and reimbursement among government and private payers once the HCPCS codes become effective.

Risks

• The company has a history of losses and may not achieve or sustain profitability.
• The company will require additional financing to carry out its plan of operations, and failure to obtain such financing may cause its business to fail.
• The company currently only has one product, the PoNS device, which is authorized for commercial distribution in Canada, Australia, and in the U.S. for treatment of MS, and may never obtain authorization and/or certification to distribute the PoNS device commercially in Europe or in the U.S. for other indications.
• The company may encounter substantial delays in planned clinical trials, and planned clinical trials may fail to demonstrate the safety and efficacy of the PoNS device to the satisfaction of regulatory authorities.
• Market awareness of the PoNS device is limited, and the neuromodulation market is new and uncertain.
• The company is reliant on third-party, single-sourced contract manufacturing, exposing it to risks that could delay sales or result in higher costs or lost product revenues including additional related risks resulting from the transition of its manufacturer.

Future Outlook

The company expects to continue to incur losses and will require additional financing beyond the second quarter of 2024. They anticipate it will take at least 24 months to obtain broad coverage and reimbursement among government and private payers once the HCPCS codes become effective.

Management Comments

• Management is focused on expanding commercialization efforts in the U.S.
• Management is working to secure reimbursement for the PoNS device.
• Management is transitioning manufacturing to a new partner to improve efficiency.

Industry Context

The neurostimulation market is competitive, with several large companies focused on surgically implanted devices. Helius is attempting to establish itself in the non-implantable neurostimulation space, which is a relatively new and uncertain market.

Comparison to Industry Standards

• The company's financial results are not directly comparable to established medical device companies due to its early stage of commercialization.
• The company's focus on non-implantable neurostimulation differentiates it from competitors primarily focused on invasive technologies.
• The company's reliance on third-party manufacturing is common in the medical device industry, but the transition to a new manufacturer introduces additional risk.
• The company's pursuit of reimbursement through HCPCS codes and engagement with CMS is a standard process for medical device companies seeking Medicare coverage.

Corporate Governance

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment if the company cannot secure additional financing.
• Employees may be impacted by potential cost-cutting measures if the company's financial situation does not improve.
• Customers may experience delays or disruptions in product availability during the manufacturing transition.
• Suppliers may face uncertainty due to the company's financial challenges.

Next Steps

• Complete the transition of manufacturing to Minnetronix.
• Continue to pursue commercial insurance coverage and Medicare reimbursement.
• Interact with CMS to seek Medicare final payment determinations for the new HCPCS codes.
• Continue clinical trials for stroke and other indications.
• Monitor the development of CMS's Transitional Coverage of Emerging Technology (TCET) program.

Key Dates

Keywords

PoNS device, neuromodulation, multiple sclerosis, gait deficit, reimbursement, HCPCS codes, Medicare, manufacturing, clinical trials, neurotechnology